Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the …
Over the last 12 months, insiders at Corbus Pharmaceuticals Holdings, Inc. have bought $53.69M and sold $1.89M worth of Corbus Pharmaceuticals Holdings, Inc. stock.
On average, over the past 5 years, insiders at Corbus Pharmaceuticals Holdings, Inc. have bought $17.94M and sold $723,889 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Cormorant Asset Management, LP (10 percent owner) — $912.79M.
The last purchase of 350,000 shares for transaction amount of $7M was made by Cormorant Asset Management, LP (10 percent owner) on 2024‑09‑20.
2024-09-20 | 10 percent owner | 350,000 3.227% | $20.01 | $7M | -8.61% | |||
2024-06-18 | Sale | Chief Executive Officer | 9,501 0.1849% | $42.24 | $401,294 | -3.04% | ||
2024-06-18 | Sale | Chief Financial Officer | 1,958 0.038% | $42.12 | $82,479 | -3.04% | ||
2024-06-17 | Sale | Chief Executive Officer | 1,770 0.0375% | $46.02 | $81,456 | -3.70% | ||
2024-06-17 | Sale | Chief Financial Officer | 6,730 0.145% | $46.77 | $314,789 | -3.70% | ||
2024-06-14 | Sale | Chief Executive Officer | 12,487 0.2886% | $50.17 | $626,425 | -14.83% | ||
2024-06-14 | Sale | Chief Financial Officer | 7,788 0.179% | $49.87 | $388,417 | -14.83% | ||
2024-03-08 | 10 percent owner | 300,000 6.1345% | $44.38 | $13.31M | -7.63% | |||
2024-03-07 | 10 percent owner | 250,000 4.6136% | $40.05 | $10.01M | +3.08% | |||
2024-02-02 | 10 percent owner | 750,000 6.5656% | $19.00 | $14.25M | +46.59% | |||
2024-01-26 | 10 percent owner | 282,632 4.1983% | $32.24 | $9.11M | +31.55% | |||
2022-08-10 | Chief Financial Officer | 20,000 0.0024% | $0.26 | $5,198 | -23.53% | |||
2022-08-10 | Chief Executive Officer | 3,800 0.0005% | $0.26 | $1,003 | -23.53% | |||
2022-08-10 | Chief Operating Officer | 5,000 0.0006% | $0.25 | $1,273 | -23.53% | |||
2022-05-16 | Chief Financial Officer | 12,000 0.0017% | $0.30 | $3,600 | -34.56% | |||
2022-05-16 | Chief Executive Officer | 10,500 0.0012% | $0.25 | $2,625 | -34.56% | |||
2022-03-10 | Chief Financial Officer | 15,000 0.0026% | $0.37 | $5,550 | -46.84% | |||
2022-03-10 | Chief Operating Officer | 10,000 0.0017% | $0.37 | $3,700 | -46.84% | |||
2022-03-09 | Chief Executive Officer | 8,600 0.0015% | $0.37 | $3,182 | -44.14% | |||
2020-12-21 | Sale | Chief Financial Officer | 87,500 0.0706% | $1.75 | $153,125 | -0.66% |
Cormorant Asset Management, LP | 10 percent owner | 2375000 19.5% | $13.00 | 5 | 0 | |
Cohen Yuval | Chief Executive Officer | 77221 0.634% | $13.00 | 25 | 3 | +10.48% |
Moran Sean F. | Chief Financial Officer | 48605 0.3991% | $13.00 | 45 | 6 | +30.87% |
Tepper Mark | President and CSO | 2101000 17.2503% | $13.00 | 1 | 0 | |
White Barbara | Chief Medical Officer | 206217 1.6931% | $13.00 | 27 | 0 | +9.31% |